Akero Therapeutics, Inc. — Director's Dealing 2021

Dec 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2021-12-08

Reporting Person: Cheng Andrew (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-08	Stock Option (Right to Buy)	$21.1	A	261662	Acquired	2031-12-07	Common Stock (261662)	Direct

Footnotes

F1: This option shall vest and become exercisable in 48 equal monthly installments commencing on December 8, 2021.